Mast cell tumor radiation
therapy for dogs
in Florida.

Incomplete margins after surgery
are not the end of treatment.

Mast cell tumors are highly variable — some behave indolently for years; others grow aggressively and metastasize early. The most critical local control decision comes after surgery: when histopathology reveals incomplete or narrow margins, adjuvant radiation can prevent local recurrence in the majority of cases.

The location of a mast cell tumor frequently determines how wide a surgical margin is achievable. Tumors on the muzzle, digits, prepuce, perianal region, and distal limbs often cannot be excised with the recommended 2–3 cm margins without causing significant functional or cosmetic compromise. In these locations, radiation therapy becomes the essential complement to surgery — treating the microscopic disease remaining at the margins with precision.

Grade matters — and so does timing

Patnaik Grade II (intermediate) and Kiupel Low-Grade MCTs have the strongest evidence base for adjuvant radiation. 1-year local control rates of 85–90% are consistently reported when CFRT follows incomplete excision. High-grade tumors benefit from local control as well, but require attention to systemic therapy because of their significant metastatic risk. Radiation should begin as soon as possible after wound healing from surgery — delay increases recurrence risk.

Inoperable mast cell tumors

When surgery is not possible — due to tumor location, size, or the owner's preference — radiation can be used as the primary local treatment. Definitive CFRT or palliative protocols can achieve meaningful tumor reduction, symptom relief, and local control without surgery.